BidaskClub cut shares of Myokardia (NASDAQ:MYOK) from a hold rating to a sell rating in a report issued on Wednesday.
A number of other brokerages have also weighed in on MYOK. Credit Suisse Group reissued an outperform rating and issued a $55.00 target price (up previously from $45.00) on shares of Myokardia in a research report on Tuesday, September 19th. TheStreet lowered Myokardia from a c rating to a d+ rating in a research report on Friday, November 3rd. Zacks Investment Research lowered Myokardia from a hold rating to a sell rating in a research report on Wednesday, October 11th. Wedbush restated an outperform rating and set a $51.00 price target on shares of Myokardia in a research note on Wednesday, September 20th. Finally, J P Morgan Chase & Co started coverage on Myokardia in a research note on Tuesday, December 12th. They set an overweight rating and a $54.00 price target for the company. Two research analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the stock. The stock presently has an average rating of Hold and a consensus target price of $54.83.
Myokardia (NASDAQ MYOK) opened at $42.85 on Wednesday. Myokardia has a 52-week low of $10.55 and a 52-week high of $49.55. The firm has a market capitalization of $1,600.00 and a PE ratio of -57.91.
In related news, CEO Anastasios Gianakakos sold 4,300 shares of the business’s stock in a transaction that occurred on Monday, November 6th. The stock was sold at an average price of $40.23, for a total transaction of $172,989.00. Following the completion of the transaction, the chief executive officer now directly owns 513,417 shares in the company, valued at approximately $20,654,765.91. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, major shareholder Rock Ventures Ii L.P. Third sold 201,400 shares of the business’s stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $43.00, for a total value of $8,660,200.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,286,713 shares of company stock valued at $55,102,695. 33.40% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of MYOK. Vanguard Group Inc. boosted its stake in Myokardia by 8.9% in the 1st quarter. Vanguard Group Inc. now owns 686,119 shares of the biotechnology company’s stock worth $9,022,000 after purchasing an additional 55,927 shares during the period. Geode Capital Management LLC boosted its stake in Myokardia by 10.7% in the 1st quarter. Geode Capital Management LLC now owns 134,730 shares of the biotechnology company’s stock worth $1,771,000 after purchasing an additional 13,057 shares during the period. Schwab Charles Investment Management Inc. boosted its stake in Myokardia by 5.8% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 43,680 shares of the biotechnology company’s stock worth $575,000 after purchasing an additional 2,394 shares during the period. Rhumbline Advisers boosted its stake in Myokardia by 45.4% in the 2nd quarter. Rhumbline Advisers now owns 18,489 shares of the biotechnology company’s stock worth $242,000 after purchasing an additional 5,773 shares during the period. Finally, State of Wisconsin Investment Board bought a new position in Myokardia in the 2nd quarter worth approximately $157,000. Institutional investors and hedge funds own 63.61% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Myokardia (MYOK) Downgraded by BidaskClub” was reported by Community Financial News and is owned by of Community Financial News. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at https://www.com-unik.info/2017/12/24/myokardia-myok-downgraded-by-bidaskclub.html.
MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.
What are top analysts saying about Myokardia? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Myokardia and related companies.